RESULTS OF THE FIRST RANDOMIZED PHASE II STUDY OF CATIONIC LIPOSOMAL PACLITAXEL (ENDOTAG™-1) TARGETING TUMOR ENDOTHELIAL CELLS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER (TNBC)

被引：0

作者：

Awada, A. ^{[1
]}

Bondarenko, I. N. ^{[2
]}

Tarasova, O. ^{[3
]}

Bonneterre, J. ^{[4
]}

Nowara, E. ^{[5
]}

Ferrero, J. M. ^{[6
]}

Bakshi, A. V. ^{[7
]}

Glasschroeder, B. ^{[8
]}

Elsasser, U. ^{[8
]}

Piccart, M. ^{[1
]}

机构：

[1] Inst Jules Bordet, B-1000 Brussels, Belgium

[2] Dnepropetrovsk State Med Acad, Dnepropetrovsk, Ukraine

[3] Ukraine Acad Med Sci, Inst Med Radiol, Kharkov, Ukraine

[4] Ctr Oscar Lambret, F-59020 Lille, France

[5] Inst M Sklodowskiej Curie, Ctr Onkol, Gliwice, Poland

[6] Ctr Antoine Lacassagne, F-06054 Nice, France

[7] Kaushalya Med Fdn, Thana, India

[8] MediGene AG, Planegg Martinsried, Germany

来源：

ANNALS OF ONCOLOGY | 2010年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：5 / 6

页数：2

共 50 条

[21] Phase IIB study of neoadjuvant panitumumab combined with carboplatin and paclitaxel (PaCT) for anthracycline-resistant triple-negative breast cancer (TNBC)
Lim, B.
Helgason, T.
Hess, K. R.
Piwnica-Worms, H.
Yang, W.
Adrada, B. E.
Rauch, G. M.
Gilcrease, M.
Symmans, F. W.
Huo, L.
Mittendorf, E. A.
Thompson, A.
Stacy, M-T L.
Debu, T.
Ueno, N. T.
CANCER RESEARCH, 2017, 77
[22] Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer
Ignatiadis, Michail
Zardavas, Dimitrios
Lemort, Marc
Wilke, Celine
Vanderbeeken, Marie-Catherine
D'Hondt, Veronique
De Azambuja, Evandro
Gombos, Andrea
Lebrun, Fabienne
Dal Lago, Lissandra
Bustin, Fanny
Maetens, Marion
Ameye, Lieveke
Veys, Isabelle
Michiels, Stefan
Paesmans, Marianne
Larsimont, Denis
Sotiriou, Christos
Nogaret, Jean-Marie
Piccart, Martine
Awada, Ahmad
PLOS ONE, 2016, 11 (07):
[23] Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer
Curigliano, Giuseppe
Pivot, Xavier
Cortes, Javer
Elias, Anthony
Cesari, Rossano
Khosravan, Reza
Collier, Mary
Huang, Xin
Cataruozolo, Patricia E.
Kern, Kenneth A.
Goldhirsch, Aron
BREAST, 2013, 22 (05): : 650 - 656
[24] Preoperative Carboplatin-Paclitaxel-Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study
Guarneri, Valentina
Dieci, Maria Vittoria
Bisagni, Giancarlo
Boni, Corrado
Cagossi, Katia
Puglisi, Fabio
Pecchi, Annarita
Piacentini, Federico
Conte, PierFranco
ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (09) : 2881 - 2887
[25] TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer
Lynce, Filipa
Stevens, Laura E.
Li, Zheqi
Brock, Jane E.
Gulvady, Anushree
Huang, Ying
Nakhlis, Faina
Patel, Ashka
Force, Jeremy M.
Haddad, Tufia C.
Ueno, Naoto
Stearns, Vered
Wolff, Antonio C.
Clark, Amy S.
Bellon, Jennifer R.
Richardson, Edward T.
Balko, Justin M.
Krop, Ian E.
Winer, Eric P.
Lange, Paulina
Hwang, E. Shelley
King, Tari A.
Tolaney, Sara M.
Thompson, Alastair
Gupta, Gaorav P.
Mittendorf, Elizabeth A.
Regan, Meredith M.
Overmoyer, Beth
Polyak, Kornelia
BREAST CANCER RESEARCH, 2024, 26 (01)
[26] TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer
Filipa Lynce
Laura E. Stevens
Zheqi Li
Jane E. Brock
Anushree Gulvady
Ying Huang
Faina Nakhlis
Ashka Patel
Jeremy M. Force
Tufia C. Haddad
Naoto Ueno
Vered Stearns
Antonio C. Wolff
Amy S. Clark
Jennifer R. Bellon
Edward T. Richardson
Justin M. Balko
Ian E. Krop
Eric P. Winer
Paulina Lange
E. Shelley Hwang
Tari A. King
Sara M. Tolaney
Alastair Thompson
Gaorav P. Gupta
Elizabeth A. Mittendorf
Meredith M. Regan
Beth Overmoyer
Kornelia Polyak
Breast Cancer Research, 26
[27] Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple-Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study
Bardia, Aditya
Krop, Ian
Meric-Bernstam, Funda
Tolcher, Anthony W.
Mukohara, Toru
Lisberg, Aaron
Shimizu, Toshio
Hamilton, Erika
Spira, Alexander I.
Papadopoulos, Kyriakos P.
Greenberg, Jonathan
Gu, Wen
Kobayashi, Fumiaki
Zebger-Gong, Hong
Kawasaki, Yui
Wong, Rie
Kogawa, Takahiro
CANCER RESEARCH, 2023, 83 (05)
[28] Results of a phase II randomized trial of cisplatin ± veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416).
Sharma, Priyanka
Rodler, Eve
Barlow, William E.
Gralow, Julie
Huggins-Puhalla, Shannon Leigh
Anders, Carey K.
Goldstein, Lori J.
Brown-Glaberman, Ursa Abigail
Thu-Tam Huynh
Szyarto, Christopher Scott
Godwin, Andrew K.
Pathak, Harsh B.
Swisher, Elizabeth M.
Radke, Marc R.
Timms, Kirsten M.
Lew, Danika L.
Miao, Jieling
Pusztai, Lajos
Hayes, Daniel F.
Hortobagyi, Gabriel N.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[29] Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51
Jung Ok Lee
Min Ju Kang
Won Seok Byun
Shin Ae Kim
Il Hyeok Seo
Jeong Ah. Han
Ji Wook Moon
Ji Hae Kim
Su Jin Kim
Eun Jung Lee
Serk In Park
Sun Hwa Park
Hyeon Soo Kim
Breast Cancer Research, 21
[30] Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51
Lee, Jung Ok
Kang, Min Ju
Byun, Won Seok
Kim, Shin Ae
Seo, Il Hyeok
Han, Jeong Ah
Moon, Ji Wook
Kim, Ji Hae
Kim, Su Jin
Lee, Eun Jung
Park, Serk In
Park, Sun Hwa
Kim, Hyeon Soo
BREAST CANCER RESEARCH, 2019, 21 (01)

← 1 2 3 4 5 →